Acasti Reports Results of GTX-102 in P-I Bridging Study for the Treatment of Ataxia Telangiectasia
Shots:
- The P-I clinical trial evaluates GTX-102 in a crossover analysis that assesses the bioavailability, PK & safety of GTX-102 oral spray (0.0125/0.05/0.1 mg/kg) vs betamethasone IM (0.1 mg/kg) & OS (0.1 mg/kg) in healthy individuals (n=48)
- The PK outcomes depicted good linearity & dose-proportionality for betamethasone blood concentrations at all dose levels of GTX-102 whereas following a high dose of GTX-102 the concentration was within the same range of exposure as betamethasone IM & OS
- Additionally, no difference was seen between the fast rate administration of GTX-102 vs slow rate whereas the Cmax of GTX-102 was within the same range of exposure as OS but was lower for IM
Ref: Globenewswire | Image: Acasti
Related News:- Ultragenyx Enters into a Partnership and Option to Acquire Agreement with GeneTx to Develop its GTX-102 for Angelman Syndrome
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
